Dr. Zheng is Professor and Chair of Pathology and Laboratory Medicine at The University of Kansas Medical Center. Dr. Zheng's research focuses on the pathogenesis of thrombotic thrombocytopenic purpura (TTP) and the mechanism of microvascular thrombosis caused by COVID-19. Dr. Zheng's passion has been in providing high-quality patient care, supporting medical and graduate education, and fostering innovative research. Dr. Zheng was the first to identify and clone ADAMTS13, a metalloprotease that cleaves von Willebrand factor. Deficiency of ADAMTS13 results in a fatal blood disorder, thrombotic thrombocytopenic purpura (TTP). Over the decades, Dr. Zheng has published more than 127 manuscripts in high-profile and peer-reviewed journals and six book chapters. Dr. Zheng is the world leader in TTP research. Additionally, Dr. Zheng serves as the standing member of the Hemostasis, Thrombosis, and Blood Transfusion (HTBT) study section at the National Institute of Health. He was an associate editor for the Journal of Thrombosis and Haemostasis and continues to serve as the Associate Editor for the Archives of Pathology and Laboratory Medicine, Journal of Clinical Medicine, Annals of Blood, Journal of Clinical and Translational Pathology, etc. Dr. Zheng has mentored several dozen trainees, including graduate students, postdoctoral fellows, junior faculty members, and physician scientists.